RANK-mediated signaling network and cancer metastasis

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 497-509

  Chu, Gina Chia Yi ^a   Chung, Leland W K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer dormancy; Cooperation in metastasis; Osteomimicry; Signal amplification; Transcription factors; 2 microglobulin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL; BONE TUMOR; DRUG EFFECTS; HUMAN; METABOLISM; METASTASIS; NEOPLASMS; PATHOLOGY; PHENOTYPE; PROTEIN PROTEIN INTERACTION; SECONDARY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BONE NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; PROTEIN INTERACTION MAPS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84905097694     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9488-7     Document Type: Review

References (133)

1. Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563-572. doi:10.1038/nrc865. (Pubitemid 37328923)
2. Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer, 3(6), 453-458. doi:10.1038/nrc1098.
3. Kang, Y., & Massague, J. (2004). Epithelial-mesenchymal transitions: twist in development and metastasis. Cell, 118(3), 277-279. doi:10.1016/j.cell. 2004.07.011.
4. Alderton, G. K. (2012). Metastasis: Converging targets. Naturforschende Review Cancer, 12(12), 793. doi:10.1038/nrc3411.
5. Hardy, K. M., Kirschmann, D. A., Seftor, E. A., Margaryan, N. V., Postovit, L. M., Strizzi, L., et al. (2010). Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Research, 70(24), 10340-10350. doi:10.1158/0008-5472.CAN-10- 0705.
6. Cui, H., Grosso, S., Schelter, F., Mari, B., & Kruger, A. (2012). On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1alpha, and miR-210. Frontiers in Pharmacology, 3, 134. doi:10.3389/fphar.2012.00134.
7. Qi, Y., Li, R. M., Kong, F. M., Li, H., Yu, J. P., & Ren, X. B. (2012). How do tumor stem cells actively escape from host immunosurveillance? Biochemical and Biophysical Research Communications, 420(4), 699-703. doi:10.1016/j.bbrc.2012.03.086.
8. Mitchell, M. J., & King, M. R. (2013). Computational and experimental models of cancer cell response to fluid shear stress. Frontiers Oncologica, 3, 44. doi:10.3389/fonc.2013.00044.
9. Di Vizio, D., Morello, M., Dudley, A. C., Schow, P. W., Adam, R. M., Morley, S., et al. (2012). Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. The American Journal of Pathology, 181(5), 1573-1584. doi:10.1016/j.ajpath.2012.07.030.
10. Odero-Marah, V. A., Wang, R., Chu, G., Zayzafoon, M., Xu, J., Shi, C., et al. (2008). Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Research, 18(8), 858-870. doi:10.1038/cr.2008.84.
11. Zhau, H. E., Odero-Marah, V., Lue, H. W., Nomura, T., Wang, R., Chu, G., et al. (2008). Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clinical and Experimental Metastasis, 25(6), 601-610. doi:10.1007/s10585-008-9183-1.
12. Zhau, H. E., Li, Q., & Chung, L. W. (2013). Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian Journal of Andrology. doi:10.1038/aja.2013.86.
13. Hu, P. Z., Chung, L. W., Berel, D., Frierson, H. F., Yang, H., Liu, C. Y., et al. (2013). Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One., 8, e73081.
14. Roodman, G. D. (2012). Genes associate with abnormal bone cell activity in bone metastasis. Cancer and Metastasis Reviews, 31(3-4), 569-578. doi:10.1007/s10555-012-9372-x.
15. Joshi, P. A., Jackson, H. W., Beristain, A. G., Di Grappa, M. A., Mote, P. A., Clarke, C. L., et al. (2010). Progesterone induces adult mammary stem cell expansion. Nature, 465(7299), 803-807. doi:10.1038/nature09091.
16. Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q. T., et al. (2009). Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone, 45(4), 669-676. doi:10.1016/j.bone.2009.06.011.
17. Sanbe, T., Tomofuji, T., Ekuni, D., Azuma, T., Irie, K., Tamaki, N., et al. (2009). Vitamin C intake inhibits serum lipid peroxidation and osteoclast differentiation on alveolar bone in rats fed on a high-cholesterol diet. Archives of Oral Biology, 54(3), 235-240. doi:10.1016/j.archoralbio.2008.11.001.
18. Roodman, G. D., & Dougall, W. C. (2008). RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treatment Reviews, 34(1), 92-101. doi:10.1016/j.ctrv.2007.09.002.
19. Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 379(9810), 39-46. doi:10.1016/S0140-6736(11) 61226-9.
20. Dougall, W. C. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research, 18(2), 326-335. doi:10.1158/1078-0432.CCR- 10-2507.
21. Chu, C. Y. (2011). The role of RANKL in prostate cancer progression and bone metastasis. Ph.D Thesis., Georgia State University,
22. Hu, P., Chu, G. C., Zhu, G., Yang, H., Luthringer, D., Prins, G., et al. (2011). Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One, 6(12), e28670. doi:10.1371/journal.pone.0028670.
23. Cox, R. F., Jenkinson, A., Pohl, K., O'Brien, F. J., & Morgan, M. P. (2012). Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One, 7(7), e41679. doi:10.1371/journal.pone.0041679.
24. Koeneman, K. S., Yeung, F., & Chung, L. W. (1999). Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39(4), 246-261. (Pubitemid 29244499)
25. Knerr, K., Ackermann, K., Neidhart, T., & Pyerin, W. (2004). Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. International Journal of Cancer, 111(1), 152-159. doi:10.1002/ijc.20223. (Pubitemid 38859297)
26. Rucci, N., & Teti, A. (2010). Osteomimicry: how tumor cells try to deceive the bone. Frontiers in Bioscience (Scholar Edition), 2, 907-915.
27. Kavitha, C. V., Deep, G., Gangar, S. C., Jain, A. K., Agarwal, C., & Agarwal, R. (2012). Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-kappaB, and AP-1 Activation in RAW264.7 cells. Molecular Carcinogenesis. doi:10.1002/mc.21959.
28. Graham, T. R., Agrawal, K. C., & Abdel-Mageed, A. B. (2010). Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cancer Science, 101(1), 103-111. doi:10.1111/j.1349-7006. 2009.01356.x.
29. Yuen, H. F., Kwok, W. K., Chan, K. K., Chua, C. W., Chan, Y. P., Chu, Y. Y., et al. (2008). TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis, 29(8), 1509-1518. doi:10.1093/carcin/bgn105.
30. Glait-Santar, C., & Benayahu, D. (2012). Regulation of SVEP1 gene expression by 17beta-estradiol and TNFalpha in preosteoblastic and mammary adenocarcinoma cells. The Journal of Steroid Biochemistry and Molecular Biology, 130(1-2), 36-44. doi:10.1016/j.jsbmb.2011.12.015.
31. Josson, S., Nomura, T., Lin, J. T., Huang, W. C., Wu, D., Zhau, H. E., et al. (2011). beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Research, 71(7), 2600-2610. doi:10.1158/0008-5472.CAN-10-3382.
32. Huang, W. C., Havel, J. J., Zhau, H. E., Qian, W. P., Lue, H. W., Chu, C. Y., et al. (2008). Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clinical Cancer Research, 14(17), 5341-5347. doi:10.1158/1078-0432.CCR-08-0793.
33. Huang, W. C., Wu, D., Xie, Z., Zhau, H. E., Nomura, T., Zayzafoon, M., et al. (2006). beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Research, 66(18), 9108-9116. doi:10.1158/0008-5472.CAN-06-1996. (Pubitemid 44521130)
34. Huang, W. C., Zhau, H. E., & Chung, L. W. (2010). Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. The Journal of Biological Chemistry, 285(11), 7947-7956. doi:10.1074/jbc.M109.092759.
35. Nomura, T., Huang, W. C., Seo, S., Zhau, H. E., Mimata, H., & Chung, L. W. (2007). Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. The Journal of Urology, 178(1), 292-300. doi:10.1016/j.juro.2007.03.007. (Pubitemid 46898459)
36. Nomura, T., Huang, W. C., Zhau, H. E., Josson, S., Mimata, H., & Chung, L. W. (2013). beta2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem. doi:ACAMC-EPUB-52886
37. Nomura, T., Huang, W. C., Zhau, H. E., Wu, D., Xie, Z., Mimata, H., et al. (2006). Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clinical Cancer Research, 12(24), 7294-7305. doi:10.1158/1078-0432.CCR-06-2060. (Pubitemid 46095401)
38. Lue, H. W., Yang, X., Wang, R., Qian, W., Xu, R. Z., Lyles, R., et al. (2011). LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One, 6(11), e27720. doi:10.1371/journal.pone.0027720.
39. Gross, M., Top, I., Laux, I., Katz, J., Curran, J., Tindell, C., et al. (2007). Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clinical Cancer Research, 13(7), 1979-1986. doi:10.1158/1078-0432.CCR-06-1156. (Pubitemid 46649863)
40. Michaelson, J. (1983). Genetics of beta-2 microglobulin in the mouse. Immunogenetics, 17(3), 219-260.
41. Solheim, J. C. (1999). Class I MHC molecules: assembly and antigen presentation. Immunological Reviews, 172, 11-19.
42. Josson, S., Matsuoka, Y., Gururajan, M., Nomura, T., Huang, W. C., Yang, X., et al. (2013). Inhibition of beta2-Microglobulin/Hemochromatosis Enhances Radiation Sensitivity by Induction of Iron Overload in Prostate Cancer Cells. PLoS One, 8(7), e68366. doi:10.1371/journal.pone.0068366.
43. Josson, S., Matsuoka, Y., Chung, L. W., Zhau, H. E., & Wang, R. (2010). Tumor-stroma co-evolution in prostate cancer progression and metastasis. Seminars in Cell and Developmental Biology, 21(1), 26-32. doi:10.1016/j.semcdb. 2009.11.016.
44. Yang, J., Qian, J., Wezeman, M., Wang, S., Lin, P., Wang, M., et al. (2006). Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10(4), 295-307. doi:10.1016/j.ccr.2006. 08.025. (Pubitemid 44512192)
45. Yang, J., Zhang, X., Wang, J., Qian, J., Zhang, L., Wang, M., et al. (2007). Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood, 110(8), 3028-3035. doi:10.1182/blood-2007-06-094417. (Pubitemid 350006957)
46. Guise, T. A., Kozlow, W. M., Heras-Herzig, A., Padalecki, S. S., Yin, J. J., & Chirgwin, J. M. (2005). Molecular mechanisms of breast cancer metastases to bone. Clinical of Breast Cancer, 5(2), S46-S53.
47. Atwood, S. X., Li, M., Lee, A., Tang, J. Y., & Oro, A. E. (2013). GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature, 494(7438), 484-488. doi:10.1038/nature11889.
48. Bershteyn, M., Atwood, S. X., Woo, W. M., Li, M., & Oro, A. E. (2010). MIM and cortactin antagonism regulates ciliogenesis and hedgehog signaling. Developmental Cell, 19(2), 270-283. doi:10.1016/j.devcel.2010.07.009.
49. Dunkel, Y., Ong, A., Notani, D., Mittal, Y., Lam, M., Mi, X., et al. (2012). STAT3 protein up-regulates Galpha-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. The Journal of Biological Chemistry, 287(50), 41667-41683. doi:10.1074/jbc.M112.390781.
50. Hassan, M. Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J. A., et al. (2012). miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. The Journal of Biological Chemistry, 287(50), 42084-42092. doi:10.1074/jbc.M112. 377515.
51. Kinoshita, T., Hanazawa, T., Nohata, N., Kikkawa, N., Enokida, H., Yoshino, H., et al. (2012). Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget, 3(11), 1386-1400.
52. Tatarano, S., Chiyomaru, T., Kawakami, K., Enokida, H., Yoshino, H., Hidaka, H., et al. (2011). miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. International Journal of Oncology, 39(1), 13-21. doi:10.3892/ijo.2011.1012.
53. Uesugi, A., Kozaki, K., Tsuruta, T., Furuta, M., Morita, K., Imoto, I., et al. (2011). The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Research, 71(17), 5765-5778. doi:10.1158/0008-5472.CAN-11-0368.
54. Yamamoto, N., Kinoshita, T., Nohata, N., Itesako, T., Yoshino, H., Enokida, H., et al. (2013). Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. International Journal of Oncology, 42(5), 1523-1532. doi:10.3892/ijo.2013.1851.
55. Yamasaki, T., Seki, N., Yoshino, H., Itesako, T., Hidaka, H., Yamada, Y., et al. (2013). MicroRNA-218 Inhibits Cell Migration and Invasion in Renal Cell Carcinoma through Targeting Caveolin-2 Involved in Focal Adhesion Pathway. The Journal of Urology, 190(3), 1059-1068. doi:10.1016/j.juro.2013.02.089.
56. Tang, Y., Kesavan, P., Nakada, M. T., & Yan, L. (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase- dependent generation of soluble EMMPRIN. Molecular Cancer Research, 2(2), 73-80. (Pubitemid 38250423)
57. Tang, Y., Nakada, M. T., Kesavan, P., McCabe, F., Millar, H., Rafferty, P., et al. (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Research, 65(8), 3193-3199. doi:10.1158/0008-5472.CAN-04-3605. (Pubitemid 40524601)
58. Tang, Y., Nakada, M. T., Rafferty, P., Laraio, J., McCabe, F. L., Millar, H., et al. (2006). Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Molecular Cancer Research, 4(6), 371-377. doi:10.1158/1541-7786.MCR-06-0042. (Pubitemid 44035156)
59. Marioni, G., Blandamura, S., Giacomelli, L., Calgaro, N., Segato, P., Leo, G., et al. (2005). Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology, 46(5), 576-582. doi:10.1111/j.1365-2559.2005.02141.x. (Pubitemid 40632315)
60. Chu, G. C.-Y., Zhau, H. E., Wang, R. Rogatko, A., Feng, X., Zayzafoon, M., Liu, Y., Farach-Carson, M. C., You, S., Kim, J., Freeman, M. R., Chung, L. W. (2013). RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer (in press).
61. Chu, G. C.-Y., Zhau, H. E., Wang, R. Rogatko, A., Feng, X., Zayzafoon, M., Liu, Y., Farach-Carson, M. C., Chung, L. W. (2013). Autocrine/paracrine RANKL-RANK signaling promotes cancer bone metastasis and establishes premetastatic niche recruiting bystander cancer cells to participate in the metastatic process. Washington, DC: American Association for Cancer Research.
62. Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. NeuroOncology, 7(2), 134-153. doi:10.1215/S1152851704001115. (Pubitemid 40590514)
63. Kimbro, K. S., & Simons, J. W. (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-Related Cancer, 13(3), 739-749. doi:10.1677/erc.1.00728.
64. Powis, G., & Kirkpatrick, L. (2004). Hypoxia inducible factor-1alpha as a cancer drug target. Molecular Cancer Therapeutics, 3(5), 647-654.
65. Smith, B. N., & Odero-Marah, V. A. (2012). The role of Snail in prostate cancer. Cell Adhesion & Migration, 6(5), 433-441. doi:10.4161/cam.21687.
66. Jiang, J., Tang, Y. L., & Liang, X. H. (2011). EMT: a new vision of hypoxia promoting cancer progression. Cancer Biology and Therapy, 11(8), 714-723.
67. Konisti, S., Kiriakidis, S., & Paleolog, E. M. (2012). Hypoxia - a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nature Reviews. Rheumatology, 8(3), 153- 162. doi:10.1038/nrrheum.2011.205.
68. McNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013). Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunologic Research, 55(1-3), 58-70. doi:10.1007/s12026-012-8349-8.
69. Shay, J. E., & Celeste Simon, M. (2012). Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Seminars in Cell and Developmental Biology, 23(4), 389-394. doi:10.1016/j.semcdb.2012.04.004.
70. Tomita, S., Kihira, Y., Imanishi, M., Fukuhara, Y., Imamura, Y., Ishizawa, K., et al. (2011). Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:inflammatory responses of hypoxia-inducible factor 1alpha (HIF-1alpha) in T cells observed in development of vascular remodeling. Journal of Pharmacological Sciences, 115(4), 433-439.
71. Brabletz, S., & Brabletz, T. (2010). The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Reports, 11(9), 670-677. doi:10.1038/embor.2010.117.
72. Guo, L., Chen, C., Shi, M., Wang, F., Chen, X., Diao, D., et al. (2013). Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. doi:10.1038/onc.2012.573.
73. Chung, L. W. (1995). The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surveys, 23, 33-42.
74. Cunha, G. R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer, 74(3 Suppl), 1030-1044.
75. Donjacour, A. A., & Cunha, G. R. (1991). Stromal regulation of epithelial function. Cancer Treatment and Research, 53, 335-364.
76. Roberts, A. B., & Sporn, M. B. (1987). Transforming growth factor-beta: potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogenesis. International Journal of Radiation Applications and Instrumentation. Part B, 14(4), 435-439.
77. Sakakura, T. (1991). New aspects of stroma-parenchyma relations in mammary gland differentiation. International Review of Cytology, 125, 165-202.
78. Chung, L. W., Huang, W. C., Sung, S. Y., Wu, D., Odero-Marah, V., Nomura, T., et al. (2006). Stromal-epithelial interaction in prostate cancer progression. Clinical Genitourinary Cancer, 5(2), 162-170. doi:10.3816/CGC.2006. n.034.
79. Clezardin, P., & Teti, A. (2007). Bone metastasis: pathogenesis and therapeutic implications. Clinical and Experimental Metastasis, 24(8), 599-608. doi:10.1007/s10585-007-9112-8.
80. Tsubochi, H., Endo, S., Oda, Y., & Dobashi, Y. (2013). Carcinoid tumor of the lung with massive ossification: report of a case showing the evidence of osteomimicry and review of the literature. International Journal of Clinical and Experimental Pathology, 6(5), 957-961.
81. Bhatia, M. (2010). Developmental biology. Microenvironment mimicry. Science, 329(5995), 1024-1025. doi:10.1126/science.1194919.
82. Bissell, M. J. (1999). Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? American Journal of Pathologists, 155(3), 675-679. doi:10.1016/S0002-9440(10)65164-4.
83. Folberg, R., Hendrix, M. J., & Maniotis, A. J. (2000). Vasculogenic mimicry and tumor angiogenesis. The American Journal of Pathology, 156(2), 361-381. doi:10.1016/S0002-9440(10)64739-6. (Pubitemid 30648785)
84. Folberg, R., & Maniotis, A. J. (2004). Vasculogenic mimicry. APMIS, 112(7-8), 508-525. doi:10.1111/j.1600-0463.2004.apm11207-0810.x.
85. Hendrix, M. J., Seftor, E. A., Hess, A. R., & Seftor, R. E. (2003). Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Reviews Cancer, 3(6), 411-421. doi:10.1038/nrc1092. (Pubitemid 37328845)
86. McDonald, D. M., Munn, L., & Jain, R. K. (2000). Vasculogenic mimicry: how convincing, how novel, and how significant? The American Journal of Pathology, 156(2), 383-388. doi:10.1016/S0002-9440(10)64740-2.
87. Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., et al. (2007). Epithelial-mesenchymal and mesenchymal- epithelial transitions in carcinoma progression. Journal of Cellular Physiology, 213(2), 374-383. doi:10.1002/jcp.21223. (Pubitemid 47509716)
88. Nauseef, J. T., & Henry, M. D. (2011). Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nature Reviews. Urology, 8(8), 428-439. doi:10.1038/nrurol.2011.85.
89. van der Pluijm, G. (2011). Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 48(1), 37-43. doi:10.1016/j.bone.2010.07.023.
90. Cogle, C. R., Theise, N. D., Fu, D., Ucar, D., Lee, S., Guthrie, S. M., et al. (2007). Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells, 25(8), 1881-1887. doi:10.1634/stemcells. 2007-0163. (Pubitemid 47258166)
91. Ping, Y. F., & Bian, X. W. (2011). Consice review: Contribution of cancer stem cells to neovascularization. Stem Cells, 29(6), 888-894. doi:10.1002/stem.650.
92. Timar, J., Tovari, J., Raso, E., Meszaros, L., Bereczky, B., & Lapis, K. (2005). Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology, 69(3), 185-201. doi:10.1159/000088069. (Pubitemid 41433577)
93. Yao, X. H., Ping, Y. F., & Bian, X. W. (2011). Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein & Cell, 2(4), 266-272. doi:10.1007/s13238-011-1041-2.
94. Danza, G., Di Serio, C., Rosati, F., Lonetto, G., Sturli, N., Kacer, D., et al. (2012). Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Molecular Cancer Research, 10(2), 230-238. doi:10.1158/1541-7786.MCR-11-0296.
95. Eisinger-Mathason, T. S., & Simon, M. C. (2010). HIF-1alpha partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis. Cancer Cell, 18(1), 3-4. doi:10.1016/j.ccr.2010.06.007.
96. McKeithen, D., Graham, T., Chung, L. W., & Odero-Marah, V. (2010). Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate, 70(9), 982-992. doi:10.1002/pros.21132.
97. Spiotto, M. T., & Chung, T. D. (2000). STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate, 42(3), 186-195.
98. Lang, S. H., Sharrard, R. M., Stark, M., Villette, J. M., & Maitland, N. J. (2001). Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. British Journal of Cancer, 85(4), 590-599. doi:10.1054/bjoc.2001.1967. (Pubitemid 32808286)
99. Lang, S. H., Stark, M., Collins, A., Paul, A. B., Stower, M. J., & Maitland, N. J. (2001). Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth and Differentiation, 12(12), 631-640. (Pubitemid 34084116)
100. Winkenwerder, J. J., Palechek, P. L., Reece, J. S., Saarinen, M. A., Arnold, M. A., Cohen, M. B., et al. (2003). Evaluating prostate cancer cell culturing methods: a comparison of cell morphologies and metabolic activity. Oncology Reports, 10(4), 783-789.
101. Baker, E. L., Bonnecaze, R. T., & Zaman, M. H. (2009). Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. Biophysical Journal, 97(4), 1013-1021. doi:10.1016/j.bpj.2009.05.054.
102. Docheva, D., Padula, D., Schieker, M., & Clausen-Schaumann, H. (2010). Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells. Biochemical and Biophysical Research Communications, 402(2), 361-366. doi:10.1016/j.bbrc.2010.10.034.
103. He, H., Yang, X., Davidson, A. J., Wu, D., Marshall, F. F., Chung, L. W., et al. (2010). Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate, 70(5), 518-528. doi:10.1002/pros.21086.
104. Xu, J., Wang, R., Xie, Z. H., Odero-Marah, V., Pathak, S., Multani, A., et al. (2006). Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate, 66(15), 1664-1673. doi:10.1002/pros.20488. (Pubitemid 44646357)
105. Rhee, H. W., Zhau, H. E., Pathak, S., Multani, A. S., Pennanen, S., Visakorpi, T., et al. (2001). Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim, 37(3), 127-140. doi:10.1290/1071-2690(2001) 037〈0127:PPAGCO〉2.0.CO;2. (Pubitemid 32423833)
106. Sung, S. Y., Hsieh, C. L., Law, A., Zhau, H. E., Pathak, S., Multani, A. S., et al. (2008). Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Research, 68(23), 9996-10003. doi:10.1158/0008-5472.CAN-08-2492.
107. Kaplun, A., Dzinic, S., Bernardo, M., & Sheng, S. (2012). Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Critical Reviews in Eukaryotic Gene Expression, 22(3), 249-258.
108. Ruppender, N. S., Morrissey, C., Lange, P. H., & Vessella, R. L. (2013). Dormancy in solid tumors: implications for prostate cancer. Cancer and Metastasis Reviews. doi:10.1007/s10555-013-9422-z.
109. Chauhan, S., & Tyagi, J. S. (2008). Interaction of DevR with multiple binding sites synergistically activates divergent transcription of narK2-Rv1738 genes in Mycobacterium tuberculosis. Journal of Bacteriology, 190(15), 5394-5403. doi:10.1128/JB.00488-08.
110. Vaistij, F. E., Gan, Y., Penfield, S., Gilday, A. D., Dave, A., He, Z., et al. (2013). Differential control of seed primary dormancy in Arabidopsis ecotypes by the transcription factor SPATULA. Proceedings of the National Academy of Sciences of the United States of America, 110(26), 10866 -10871. doi:10.1073/pnas.1301647110.
111. Nadendla, S. K., Hazan, A., Ward, M., Harper, L. J., Moutasim, K., Bianchi, L. S., et al. (2011). GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state. PLoS One, 6(5), e20271. doi:10.1371/journal.pone.0020271.
112. Shigemura, K., Huang, W. C., Li, X., Zhau, H. E., Zhu, G., Gotoh, A., et al. (2011). Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. Prostate, 71(16), 1711-1722. doi:10.1002/pros.21388.
113. Javelaud, D., Alexaki, V. I., Dennler, S., Mohammad, K. S., Guise, T. A., & Mauviel, A. (2011). TGF-beta/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Research, 71(17), 5606-5610. doi:10.1158/0008-5472.CAN-11-1194.
114. Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell, 20(6), 701-714. doi:10.1016/j.ccr.2011.11.002.
115. Shiozawa, Y., Pedersen, E. A., & Taichman, R. S. (2010). GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Experimental Hematology, 38(2), 132-140. doi:10.1016/j.exphem.2009.11.002.
116. Taichman, R. S., Patel, L. R., Bedenis, R., Wang, J., Weidner, S., Schumann, T., et al. (2013). GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One, 8(4), e61873. doi:10.1371/journal.pone.0061873.
117. Lim, P. K., Bliss, S. A., Patel, S. A., Taborga, M., Dave, M. A., Gregory, L. A., et al. (2011). Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Research, 71(5), 1550-1560. doi:10.1158/0008-5472.CAN-10-2372.
118. Almog, N., Briggs, C., Beheshti, A., Ma, L., Wilkie, K. P., Rietman, E., et al. (2013). Transcriptional changes induced by the tumor dormancy-associated microRNA-190. Transcription, 4(4).
119. Almog, N., Ma, L., Schwager, C., Brinkmann, B. G., Beheshti, A., Vajkoczy, P., et al. (2012). Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One, 7(8), e44001. doi:10.1371/journal.pone.0044001.
120. Bidard, F. C., Pierga, J. Y., Vincent-Salomon, A., & Poupon, M. F. (2008). A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer and Metastasis Reviews, 27(1), 5-10. doi:10.1007/s10555-007-9103-x.
121. Pathak, S., Nemeth, M. A., Multani, A. S., Thalmann, G. N., von Eschenbach, A. C., & Chung, L. W. (1997). Can cancer cells transform normal host cells into malignant cells? British Journal of Cancer, 76(9), 1134-1138. (Pubitemid 27448008)
122. Liu, Q., Russell, M. R., Shahriari, K., Jernigan, D. L., Lioni, M. I., Garcia, F. U., et al. (2013). Interleukin-1beta promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Research, 73(11), 3297-3305. doi:10.1158/0008-5472.CAN-12-3970.
123. Giatromanolaki, A., Koukourakis, M. I., Koutsopoulos, A., Mendrinos, S., & Sivridis, E. (2012). The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biology and Therapy, 13(13), 1284-1289. doi:10.4161/cbt.21785.
124. Sotgia, F., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Pestell, R. G., & Lisanti, M. P. (2011). Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research, 13(4), 213. doi:10.1186/bcr2892.
125. Tumati, V., Kumar, S., Yu, L., Chen, B., Choy, H., & Saha, D. (2013). Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncology Reports, 29(3), 1094-1100. doi:10.3892/or.2012.2198.
126. Pan, B. S., Chan, G. K., Chenard, M., Chi, A., Davis, L. J., Deshmukh, S. V., et al. (2010). MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Research, 70(4), 1524 -1533. doi:10.1158/0008-5472.CAN-09-2541.
127. Munshi, N., Jeay, S., Li, Y., Chen, C. R., France, D. S., Ashwell, M. A., et al. (2010). ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Molecular Cancer Therapeutics, 9(6), 1544-1553. doi:10.1158/1535-7163.MCT-09-1173.
128. Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., et al. (2011). Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular Cancer Therapeutics, 10(12), 2298-2308. doi:10.1158/1535-7163.MCT-11-0264.
129. Sen, B., Peng, S., Saigal, B., Williams, M. D., & Johnson, F. M. (2011). Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clinical Cancer Research, 17(3), 514-524. doi:10.1158/1078-0432.CCR-10-1617.
130. Harvey, S. R., Porrini, M., Stachl, C., MacMillan, D., Zinzalla, G., & Barran, P. E. (2012). Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ionmobility mass spectrometry. Journal of the American Chemical Society, 134(47), 19384-19392. doi:10.1021/ja306519h.
131. Kim, J., Roh, M., & Abdulkadir, S. A. (2010). Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer, 10, 248. doi:10.1186/1471-2407-10-248.
132. Carmody, L. C., Germain, A., Morgan, B., VerPlank, L., Fernandez, C., Feng, Y., et al. (2010). Identification of a Selective Small-Molecule Inhibitor of Breast Cancer Stem Cells - Probe 2. In Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD).
133. Park, C. Y., Son, J. Y., Jin, C. H., Nam, J. S., Kim, D. K., & Sheen,